Biomarker Market
Biomarker Market Study by Cardiovascular Diseases, Cancer, Neurological Diseases, and Immunological Diseases for Safety, Efficacy, and Validation from 2024 to 2034
Analysis of Biomarker Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Biomarkers Market Outlook (2024 to 2034)
Revenue from the sales of biomarkers is expected to reach US$ 74.92 billion in 2024, as revealed in the updated market report published by Fact.MR. The global biomarkers market size is approximated to expand at a double-digit CAGR of 15% and reach a value of US$ 303.98 billion by the end of 2034.
In the recent past, there has been an increase in cases of fatal diseases, including cardiovascular disorders, diabetes, and cancer. One of the primary factors responsible for this is lifestyle changes. The use of biomarkers for the diagnosis of infectious and chronic diseases has become more common.
For instance :
- In 2020, Frontiers mentioned some potential MicroRNA-based biomarkers, which were identified for the diagnosis of infectious diseases, including Ebola, influenza infections, HIV, rhinoviruses, malaria, tuberculosis, and Hendra virus. They aimed to facilitate early diagnosis of infectious diseases.
Innovative treatments combining biomarkers with existing or new medicines are being launched in the healthcare sector. Biomarkers are utilized for the treatment of neurological diseases for tracking brain health while measuring molecules. It has become easier to develop neurological treatment solutions with these biomarkers, facilitated by faster drug development, early diagnosis, and noninvasive testing.
The emergence of digital biomarkers has assisted pharmaceutical companies with supplementary and contextual information for making decisions during clinical trials. In addition, they play a pivotal role in selecting targeted therapies addressing the molecular characteristics of tumors.
- Worldwide demand for biomarkers for use in cancer treatment is evaluated to accelerate at a CAGR of 15.4% and reach a value of US$ 116.52 billion by the end of 2034.
- North America is forecasted to account for 35.2% of the global biomarker market share by 2034-end.
- Sales of biomarkers in China are projected to climb at 19.6% CAGR and reach US$ 33.78 billion by 2034.
| Report Attribute | Detail |
|---|---|
| Biomarker Market Size (2024E) | US$ 74.92 Billion |
| Forecasted Market Value (2034F) | US$ 303.98 Billion |
| Global Market Growth Rate (2024 to 2034) | 15% CAGR |
| Market Share of Safety Biomarkers (2034F) | 36.5% |
| South Asia & Pacific Market Share (2034F) | 21.8% |
| South Korea Market Growth Rate (2024 to 2034) | 17% CAGR |
| Key Companies Profiled | Agilent Technologies, Inc.; Qiagen; Abbot Laboratories; F. Hoffman-La Roche Ltd.; Merck KGaA; Siemens Healthineers AG; Epigenetics AG; Bio-Rad Laboratories Inc.; General Electric; Thermo Fisher Scientific Inc.; PerkinElmer Inc.; Johnson & Johnson Services Inc. |
Don't Need a Global Report?
save 40%! on Country & Region specific reports
What Factors are Audibly Promulgating Biomarker Demand?
“Growing Use of Biomarkers in Diagnostics”
Compared to conventional diagnostic tools, modern diagnostic equipment ensures early, consistent, and accurate results. Biomarkers are being integrated with modern key imaging and advanced data management technologies. Further, these tools assist in early disease detection. Medical practices need an accurate diagnosis of conditions and illnesses. Diagnostic biomarkers determine if a patient with a particular medical condition requires specific treatment or must be enrolled for clinical trial investigation.
It has been recognized that various diseases with subtypes have different responses or prognoses to a specific treatment. There has been an increase in the use of diagnostic biomarkers in symptomatic patients compared to screening biomarkers.
“Increasing Cases of Cancer Contributing to Growing Demand for Biomarkers”
In recent years, there has been a significant increase in cancer cases. Cancer is becoming one of the prominent reasons for death globally, according to the World Health Organization. Increasing cancer cases are owing to poor dietary habits, lazy lifestyles, and smoking. Biomarkers are used to provide information about this disease. There are some unique patterns associated with each patient’s cancer, which affect the treatment process. They are utilized for monitoring disease development and risk assessment with the assistance of biomarkers.
Which Key Challenges are Prevalent in the Global Market?
“Expensive and Time-consuming R&D Procedures for Biomarker Medicines”
Huge capital is required for biomarkers, which has been affecting R&D activities related to the diagnosis and development of medicines. In addition, biomarker validation is a time-consuming procedure, which adversely impacts the productivity of market players.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Which Biomarker Market Trends are Paving the Way for Startups?
“Growing Investments in Identifying Disease Preventing Biomarkers”
Some areas of interest for startups in the global market include biomarker pharmaceuticals, biomarker strategies, and biomarker science. Among these, biomarker science is becoming more popular. It is engaged in identifying disease prevention biomarkers using proteomics and genomics technology. Cartilage degeneration markers, exercise and oxidation stress markers, and preventive medicines are some discovered biomarkers. New market players are offering services in planning clinical trials of functional materials and functional foods.
Country-wise Insights
North America is forecasted to hold a 35.2% share of the global market by the end of 2034, as stated in the research report prepared by skilled analysts at Fact.MR, a market research and competitive intelligence provider. Increased disease burden and improvements in healthcare infrastructure are contributing to increased demand for biomarkers. Moreover, the presence of key providers in the region, such as Merck & Co., Bio-Rad Laboratories, Inc., Abbot, and Thermo Fisher Scientific, is also contributing to biomarker market growth.
Why is the United States Exhibiting a Higher Demand for Biomarkers?
“Rapidly Increasing Cases of Chronic Diseases in the Country”
| Attribute | United States |
|---|---|
| Market Value (2024E) | US$ 23.09 Billion |
| Growth Rate (2024 to 2034) | 16.5% CAGR |
| Projected Value (2034F) | US$ 106.44 Billion |
The United States is analyzed to capture a share of 80.7% of the market in North America by 2034-end. In the past few years, there has been an increase in the number of U.S. FDA-approved drugs containing molecular biomarkers. These biomarkers are identified and validated for developing drugs and assisting in drug approval. Rapidly rising cases of chronic diseases and an increase in drug development and approvals are complementing biomarker market size expansion in the United States.
What Makes India a Key Market for Biomarker Suppliers?
“Increasing Investments in R&D Activities for Drug Development”
| Attribute | India |
|---|---|
| Market Value (2024E) | US$ 3.82 Billion |
| Growth Rate (2024 to 2034) | 22.6% CAGR |
| Projected Value (2034F) | US$ 29.38 Billion |
India is evaluated to occupy 71.4% of the South Asia & Pacific market share by the end of 2034. Flourishing pharmaceutical industry in the country is leading to increased investments in R&D activities using biomarkers for drug development. Supportive policies and programs for outpatient and in-patient procedures for disease diagnosis is also contributing to the rising demand for biomarkers.
What are the Growth Driving Factors for the South Korean Market?
“Surging Use of Biomarkers in Personalized Medicine”
| Attribute | South Korea |
|---|---|
| Market Value (2024E) | US$ 3.11 Billion |
| Growth Rate (2024 to 2034) | 17% CAGR |
| Projected Value (2034F) | US$ 15 Billion |
South Korea is forecasted to account for 26.7% of the East Asian market share by 2034-end. Biomarkers are significantly used in developing personalized medicine in the country. In addition, revenue in the market is being increased with the growing use of biomarkers in disease development for further use in cancer diagnosis.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Category-wise Insights
Worldwide demand for biomarkers for drug discovery and development applications is projected to accelerate at a CAGR of 15.3% and reach a value of US$ 108.59 billion by the end of 2034. They play a crucial role in medical practice and drug development by offering information about patient status in clinical settings. Biomarkers provide information about pharmacodynamic activity, efficacy, and safety throughout drug development.
Which Type Biomarker Accounts for High Revenue Generation?
“Increasing Application of Safety Biomarkers for Neurological Disease Treatment”
| Attribute | Safety |
|---|---|
| Segment Value (2024E) | US$ 26.91 Billion |
| Growth Rate (2024 to 2034) | 15.2% CAGR |
| Projected Value (2034F) | US$ 110.81 Billion |
Safety biomarkers are calculated to account for 36.5% share of the global market by the end of 2034. In recent years, there has been a noteworthy increase in the use of safety biomarkers for treating neurological diseases. In addition, biomarkers are also used for the treatment of various other diseases such as kidney disorders and cardiovascular diseases. Moreover, rising awareness about regular health checkups and the risk of developing certain diseases such as cardiovascular diseases and cancer are contributing to the increased demand for biomarkers.
For Which Disease is Biomarkers Significantly Used?
“High Popularity of Biomarkers for Cancer Detection and Treatment”
| Attribute | Cancer |
|---|---|
| Segment Value (2024E) | US$ 27.88 Billion |
| Growth Rate (2024 to 2034) | 15.4% CAGR |
| Projected Value (2034F) | US$ 116.52 Billion |
Biomarkers for use in cancer treatment are calculated to contribute a share of 38.3% of global market revenue by 2034. Increasing use of biomarkers for prognosis and monitoring treatment against cancer is driving their demand in the healthcare industry. Multiple methods, such as non-invasive and invasive, are used for cancer detection through biomarkers. They are used as pivotal biological molecules for cancer detection at different stages, thereby helping in treatment procedures.
Competitive Landscape
Key players in the biomarker market are actively working to identify new application areas and thereby are investing in R&D activities. Agreements, partnerships, acquisition, and new product development are some of the strategies helping market players gain a competitive edge. In addition, offering quality products and effectively managing the supply chain system also assist market players to secure and expand their footprints.
For instance :
- F. Hoffman La Roche Ltd., in April 2021, launched two new cardiac biomarker tests, the NTproBNP (N-Terminal Pro Brain Natriuretic Peptide) and cTnThs (Sensitive Cardiac Troponin) Test. These standard biomarkers support managing cardiovascular diseases, helping physicians diagnose heart functioning and efficiently manage any failure.
- Thermo Fisher Scientific, in July 2020, entered into an agreement with Chugai to expand the application of Oncomine Dx target tests. The companies are planning to use these tests with NSCLC (non-small cell lung cancer) and accelerate the area of local biomarker tests.
Fact.MR provides detailed information about the price points of key manufacturers of biomarkers positioned across the world, sales growth, production capacity, and speculative technological expansion, in the recently updated market report.
Segmentation of Biomarker Market Research
-
By Disease :
- Cardiovascular Diseases
- Cancer
- Neurological Diseases
- Immunological Diseases
- Other Disease Types
-
By Type :
- Safety
- Efficacy
- Validation
-
By Application :
- Diagnostics
- Drug Discovery & Development
- Personalized Medicines
- Other Applications
-
By Region :
- North America
- Latin America
- Western Europe
- Eastern Europe
- East Asia
- South Asia & Pacific
- MEA
- FAQs -
How big is the biomarker market in 2024?
The global biomarker market is expected to reach US$ 74.92 billion in 2024.
What is the demand outlook for biomarkers for 2034?
Worldwide sales of biomarkers are approximated to reach US$ 303.98 billion by the end of 2034.
At what CAGR are the sales of biomarkers evaluated to climb?
The market for biomarkers is projected to advance at 15% CAGR from 2024 to 2034.
What is the contribution of North America to global market revenue?
North America is evaluated to account for 35.2% of the global market share by 2034.
At what rate is the demand for biomarkers projected to increase in South Korea?
The market in South Korea is analyzed to accelerate at a CAGR of 17% from 2024 to 2034.
How much share of the global market are safety biomarkers expected to occupy?
Safety biomarkers are forecasted to account for 36.5% share of global market revenue by 2034.
Who are some of the prominent suppliers of biomarkers?
Agilent Technologies, Inc., Qiagen, Abbot Laboratories, F. Hoffman-La Roche Ltd., and Merck KGaA are some of the leading market players.
What are biomarkers in pharma?
Biomarker indicates changes in protein state or expression correlating with the progression or risk of a disease or with susceptibility to disease treatment.
Biomarker Market